Enara Bio Company

Enara Bio is a science-led company targeting the T-cell/cancer cell interface (the вАЬimmune synapseвАЭ) to develop new targeted cancer immunotherapies designed to treat a broad patient population. Enara Bio focuses on discovering and developing therapeutic cancer vaccines utilizing novel antigens derived from endogenous retroviral (ERV)-related DNA sequences.

Estimated Revenue: $1M to $10M
Funding Status: Early Stage Venture
Headquarters: London, England, United Kingdom
Total Funding: 17500000
Last Funding Date: 2019-11-06
Investors Number: 2
Founded Date: 2016-01-01
Industry: Tumor-Specific Antigens
Last Funding Type: Series A
Employee Number: 11-50